Company Overview

Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing drug candidates that leverage its proprietary polymer technology platform to improve the delivery, tolerability, and pharmacokinetic profile of therapeutics. The company operates within the biopharmaceutical and central nervous system (CNS) therapeutics industries, with a primary emphasis on neurology and other indications where sustained drug exposure and reduced toxicity may provide clinical advantages. Its core technology platform, known as POZ Platform™, is based on a synthetic, water-soluble polymer designed as an alternative to polyethylene glycol (PEG) for drug conjugation and delivery applications.

The company’s primary business activities center on advancing internally developed therapeutic candidates and evaluating broader applications of the POZ Platform™ through potential collaborations and licensing opportunities. Serina’s lead development efforts have focused on CNS-related disorders, including Parkinson’s disease, through reformulated or optimized therapeutic approaches intended to improve patient outcomes. The company evolved from earlier polymer science and drug-delivery research efforts and has repositioned itself as a therapeutics-focused biotechnology company through public-market financing activities, strategic restructuring, and technology platform development.

Business Operations

Serina Therapeutics generates value primarily through research and development activities associated with its proprietary polymer conjugation technologies and therapeutic pipeline. The company’s operations are organized around the advancement of POZ Platform™-enabled therapeutics, including preclinical and clinical development programs. Its business model includes internal drug development, intellectual property generation, and the potential monetization of technology applications through partnerships, licensing arrangements, or co-development agreements.

The company operates principally in the United States, with activities including laboratory research, clinical development planning, regulatory engagement, and intellectual property management. Serina controls proprietary polymer chemistry assets, formulation technologies, and related patent portfolios associated with the POZ Platform™. Public disclosures indicate that the company has evaluated strategic collaborations and external development relationships to support manufacturing, research, and clinical execution functions. Data regarding large-scale international subsidiaries or material joint ventures remains limited in publicly available filings.

Strategic Position & Investments

Serina’s strategic direction centers on advancing differentiated therapeutics enabled by its polymer delivery technology while expanding the applicability of the POZ Platform™ across multiple drug classes. The company has emphasized the potential advantages of its platform relative to PEGylation technologies, including biodegradability, tunable molecular architecture, and potentially improved safety and pharmacological performance. Its growth strategy includes progressing lead candidates through clinical development and pursuing broader pharmaceutical applications for its polymer technology.

The company has also pursued capital markets activity and corporate restructuring initiatives to support long-term development objectives. Strategic investments have focused primarily on research and development capabilities, intellectual property protection, and clinical advancement rather than large-scale acquisitions. Publicly available disclosures identify the company’s therapeutic and platform assets as its principal strategic holdings. Information regarding material portfolio-company investments or major acquisition activity is limited based on currently available public filings.

Geographic Footprint

Serina Therapeutics is headquartered in the United States and primarily conducts operations within the domestic biotechnology sector. Its research, corporate governance, and development activities are centered in the U.S., where the company also engages with regulatory authorities, investors, and clinical-development partners. The company’s market presence is primarily associated with U.S. public capital markets following its listing under the ticker symbol SER.

Although Serina does not currently maintain a broad multinational commercial footprint comparable to large pharmaceutical companies, its technology platform is designed for potential applicability across global pharmaceutical markets. The company’s intellectual property strategy includes patent protections that may extend internationally, and future licensing or partnership opportunities could expand its operational reach into additional regions including Europe and Asia-Pacific. Public information regarding significant international operational infrastructure remains limited.

Leadership & Governance

Serina Therapeutics is led by an executive team with experience in biotechnology development, pharmaceutical strategy, finance, and drug delivery technologies. Company leadership has consistently emphasized advancing the POZ Platform™ as a differentiated polymer technology capable of supporting next-generation therapeutics with improved pharmacokinetic and safety characteristics. Governance oversight is provided through the company’s board structure and public-company reporting obligations, including disclosures contained in SEC filings and investor materials.

Key executives and leadership figures include:

• Steven A. Ledger – Chief Executive Officer
• Tom Niesel – Chairman of the Board
• Mark J. Corrigan, M.D. – Director
• Michael S. Weiss – Director
• Joseph C. Turner – Chief Financial Officer

Certain executive and board-role details may change over time based on subsequent company filings and governance updates. Data has been cross-referenced against publicly available company disclosures and regulatory filings; however, some leadership information may be subject to revision based on the timing of the most recent filings available to the public.